Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug R&D For Global Diseases Needs Revenue Incentives – BIO Meeting

Executive Summary

Development of vaccines for diseases prevalent in the developing world would be most effectively promoted by revenue-enhancing incentives, speakers at a Biotechnology Industry Association/Bill & Melinda Gates Foundation forum said

You may also be interested in...



R&D “Pull” Incentives For Vaccines Need $250 Mil. Guarantee – Brookings

Incentive programs to encourage development of vaccines for diseases of the developing world would need to ensure a market of $250 mil.-$500 mil. to be effective, Brookings Institution Senior Fellow Michael Kremer, PhD, said

R&D “Pull” Incentives For Vaccines Need $250 Mil. Guarantee – Brookings

Incentive programs to encourage development of vaccines for diseases of the developing world would need to ensure a market of $250 mil.-$500 mil. to be effective, Brookings Institution Senior Fellow Michael Kremer, PhD, said

Bioterror Patent Extensions Offered To Big Firms Under Revised Lieberman Bill

Large biotech firms producing counterterrorism measures could receive a two-year extension of a patent for another product under legislation introduced by Sen. Joseph Lieberman (D-Conn.)

UsernamePublicRestriction

Register

PS040939

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel